These preclinical studies have shown that approximately 50–60% of AML cell lines and patients-derived AML samples are sensitive to MDM2 inhibition (Long et al, 2010; Weisberg et al, 2015). The gene discussed is MDM2; the disease is acute myeloid leukemia.